This is reflected in the raft of mutants and variants of IL-7R components and downstream signaling molecules that have been identified in the context of immunodeficiencies, autoimmune disorders and lymphoid malignancies, but also through the use of pathway modulators as therapeutics. This evidence concerns the gene IL7R and immunodeficiency disease.